1921
image of Evidence of Microbiome–Drug Interactions between the Antimalarial Lumefantrine and Gut Microbiota in Mice
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
USD
Buy:$15.00

Abstract

The antimalarial drug lumefantrine (LF) exhibits erratic pharmacokinetics (PK). Intersubject variability might be attributed, in part, to differences in the gut microbiome–mediated drug metabolism. We assessed LF disposition in healthy mice stratified by enterotype to explore associations between the gut microbiota and LF PK. Gut microbiota enterotypes were classified according to abundance and diversity indices from 16S rRNA sequencing. Pharmacokinetic parameters were computed using noncompartmental analysis. Two distinctive enterotypes were identified. Maximal concentration ( ) and total drug exposure measured as the area under the drug concentration–time curve (AUC) differed significantly between the groups. The mean and SD of were 660 ± 220 ng/mL versus 390 ± 59 ng/mL ( = 0.02), and AUC was 9,600 ± 2,800 versus 5,800 ± 810 ng × h/mL ( = 0.01). In healthy mice intragastrically dosed with the antimalarial drug LF in combination with artemether, LF exposure was associated with the gut bacterial community structure. Studies of xenobiotic–microbiota interactions can inform drug posology and elucidate mechanisms of drug disposition.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0333
2020-07-06
2020-09-22
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0333
Loading
  • Received : 22 Apr 2020
  • Accepted : 28 May 2020
  • Published online : 06 Jul 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error